GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$45.12 USD
-0.03 (-0.07%)
Updated May 24, 2024 04:00 PM ET
After-Market: $45.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum A VGM
Price, Consensus and EPS Surprise
GSK 45.12 -0.03(-0.07%)
Will GSK be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for GSK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GSK
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
GSK: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
Other News for GSK
Zantac Verdict: Jury Finds No Link To Colon Cancer In Initial Trial, GSK And Boehringer Prevail In First Zantac Cancer Lawsuit
Jefferies healthcare analyst holds an analyst/industry conference call
Dodge & Cox International Stock Fund Q1 2024 Shareholder Letter
Dodge & Cox Global Stock Fund Q1 2024 Shareholder Letter
LONDON MARKET OPEN: FTSE 100 falls; retail sales plunge in April